Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 6Gliosarcoma 6Glioblastoma 6Endometrial Neoplasms 6Carcinoma, Renal Cell 6Sarcoma 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Rhabdomyosarcoma 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Breast Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma 2

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1romidepsin 1antineoplaston AS 2-1 1antineoplaston A10 1Streptozocin 1Sorafenib 1Sirolimus 1Oxaliplatin 1Melphalan 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Floxuridine 1Complementary Therapies 1Cisplatin 1Capecitabine 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Islet Cell × temsirolimus × Clear all
NCT00093782 2017-02-07

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 12 charts

Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡